Overview

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2040-07-01

Target enrollment:

Participant gender:

Summary

This research study is investigating whether alpha beta T-cell depleted hematopoietic stem cell transplant (HSCT) can be an immune system replacement for Crohn disease patients and whether this is safe and effective for patients with early onset, medically refractory Crohn disease.

Phase:

PHASE1

Details

Lead Sponsor:

Stanford University

Treatments:

Clofarabine
Fibroblast Growth Factor 7
Melphalan
Prednisone
Rituximab
Whole-Body Irradiation